{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:51:48Z","timestamp":1788191508376,"version":"build-2803163510"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejpb.2017.03.015","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T08:34:45Z","timestamp":1490085285000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Novel strategies in the oral delivery of antidiabetic peptide drugs \u2013 Insulin, GLP 1 and its analogs"],"prefix":"10.1016","volume":"115","author":[{"given":"Ruba","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Cs\u00f3ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0005","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharm. J."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0010","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrd1695","article-title":"Protein drug stability: a formulation challenge","volume":"4","author":"Frokjaer","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b0015","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2017.03.015_b0020","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","article-title":"Targeting of gastrointestinal tract for amended delivery of protein\/peptide therapeutics: strategies and industrial perspectives","volume":"196","author":"Pawar","year":"2014","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0025","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejpb.2017.03.015_b0030","series-title":"Therapeutic Peptides and Proteins. Formulation, Processing, and Delivery Systems","author":"Banga","year":"2006"},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0035","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1359-6446(03)02623-0","article-title":"Peptide and protein drug delivery to and into tumors: challenges and solutions","volume":"8","author":"Torchilin","year":"2003","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0040","first-page":"1","article-title":"Diabetes mellitus \u2013 a devastating metabolic disorder","volume":"40","author":"Piero","year":"2014","journal-title":"Asian J. Biomed. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0045","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijdm.2011.01.011","article-title":"Public health and prevention of blindness in diabetes","volume":"3","author":"Stef\u00e1nsson","year":"2015","journal-title":"Int. J. Diabetes Mellitus"},{"key":"10.1016\/j.ejpb.2017.03.015_b0050","doi-asserted-by":"publisher","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0055","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijdm.2009.08.001","article-title":"Chronic complications of diabetes mellitus in newly diagnosed patients","volume":"2","author":"Heydari","year":"2010","journal-title":"Int. J. Diabetes Mellitus"},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0060","doi-asserted-by":"publisher","first-page":"G956","DOI":"10.1152\/ajpgi.00107.2011","article-title":"A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems","volume":"301","author":"Card","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0065","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/aic.690410814","article-title":"Transdermal delivery of peptide and protein drugs: an overview","volume":"41","author":"Amsden","year":"1995","journal-title":"AIChE J."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0070","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0168-3659(96)01353-3","article-title":"Enhancement of the intestinal absorption of peptides and nanopeptides","volume":"41","author":"Aungst","year":"1996","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0075","first-page":"1443","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2014","journal-title":"Therap. Drug Del."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0080","first-page":"331","article-title":"Recent progress in peptides and proteins delivery by noninvasive routes","volume":"8","author":"Wearly","year":"1991","journal-title":"Cri. Rev. Ther. Drug Car. Syst."},{"key":"10.1016\/j.ejpb.2017.03.015_b0085","series-title":"Pharmaceutical Preformulation and Formulation: A Practical Guide From Candidate Drug Selection to Commercial Dossage Form","author":"Gibson","year":"2009"},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0090","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138920106777950852","article-title":"Novel delivery technologies for protein and peptide therapeutics","volume":"7","author":"Kumar","year":"2006","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0095","first-page":"367","article-title":"Noninvasive routes of proteins and peptides drug delivery","volume":"73","author":"Jitendra","year":"2011","journal-title":"Indian J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0100","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tibtech.2009.07.009","article-title":"Therapeutic application of peptides and proteins: parenteral forever?","volume":"27","author":"Antosova","year":"2009","journal-title":"Trends Biotechnol."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0105","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/nnm.10.143","article-title":"Nanocarriers for pulmonary administration of peptides and therapeutic proteins","volume":"6","author":"Andrade","year":"2011","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0110","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2174\/0929866521666140807112148","article-title":"Novel non-invasive protein and peptide drug delivery approaches","volume":"21","author":"Wallis","year":"2014","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.ejpb.2017.03.015_b0115","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.2147\/IJN.S81715","article-title":"PH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin","volume":"10","author":"Sun","year":"2015","journal-title":"J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23937\/2377-3634\/1410006","article-title":"Recent advances in insulin therapy for diabetes","volume":"1","author":"Ahmad","year":"2014","journal-title":"Int. J. Diabetes Clin. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0125","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jfda.2015.01.007","article-title":"Application of polymeric nanoparticles and micelles in insulin oral delivery","volume":"23","author":"Alai","year":"2015","journal-title":"J. Food Drug Anal."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0130","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.biotechadv.2015.02.010","article-title":"Polymer-based nanoparticles for oral insulin delivery: revisited approaches","volume":"33","author":"Fonte","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2017.03.015_b0135","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2016.02.031","article-title":"Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation","volume":"227","author":"Alibolandi","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.03.015_b0140","first-page":"13","article-title":"Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes","volume":"74","author":"Sharma","year":"2015","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0145","doi-asserted-by":"crossref","first-page":"C183","DOI":"10.1152\/ajpcell.1991.260.2.C183","article-title":"Functional biology of intestinal goblet cells","volume":"260","author":"Specian","year":"1991","journal-title":"Am. J. Phys."},{"issue":"36","key":"10.1016\/j.ejpb.2017.03.015_b0150","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1016\/j.biomaterials.2011.08.087","article-title":"A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery","volume":"32","author":"Chen","year":"2011","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0155","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of Incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0160","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"295","author":"Sandoval","year":"2015","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0165","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/S0168-8227(11)70011-0","article-title":"Incretin effect: GLP-1, GIP, DPP4","volume":"93","author":"Kazakos","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0170","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0175","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/clpt.2009.159","article-title":"Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects","volume":"86","author":"Steinert","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2017.03.015_b0180","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/753569","article-title":"Cytotoxicity and biological efficacy of exendin-4-encapsulated solid lipid nanoparticles in INS-1 cells","author":"Jun","year":"2015","journal-title":"J. Nanomater."},{"key":"10.1016\/j.ejpb.2017.03.015_b0185","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2015.09.012","article-title":"Improved oral absorption of exenatide using an original Nanoencapsulation and microencapsulation approach","volume":"217","author":"Kochavi","year":"2015","journal-title":"J. Control. Release"},{"issue":"19-20","key":"10.1016\/j.ejpb.2017.03.015_b0190","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2017.03.015_b0195","series-title":"Delivery Technologies for Biopharmaceuticals Peptides, Proteins, Nucleic Acid and Vaccines","author":"Jorgensen","year":"2009"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0200","first-page":"778","article-title":"Commercial challenges and emerging trends in oral delivery of peptide and protein drugs: a review","volume":"2","author":"Sharma","year":"2011","journal-title":"Res. J. Pharm. Biol. Chem. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2017.03.015_b0205","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1163\/156856208786440479","article-title":"Engineering strategies to enhance nanoparticle-mediated oral delivery","volume":"19","author":"Yamanaka","year":"2008","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0210","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.reactfunctpolym.2010.10.002","article-title":"Oral protein delivery: current status and future prospect","volume":"71","author":"Park","year":"2011","journal-title":"React. Funct. Polym."},{"issue":"7","key":"10.1016\/j.ejpb.2017.03.015_b0215","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev."},{"issue":"7\u20138","key":"10.1016\/j.ejpb.2017.03.015_b0220","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/00498250701867889","article-title":"Structure, function and regulation of p-glycoprotein and its clinical relevance in drug disposition","volume":"38","author":"Zhou","year":"2008","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0225","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2017.03.015_b0230","series-title":"Challenges in Delivery of Therapeutic Genomics and Proteomics","author":"Misra","year":"2011"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0235","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.1208\/pt060116","article-title":"Eudragit S100 entrapped insulin microspheres for oral delivery","volume":"6","author":"Jain","year":"2005","journal-title":"AAPS Pharm. Sci. Tech."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0240","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/jb\/mvn134","article-title":"Modification of antimicrobial peptide with low molar mass poly(ethylene glycol)","volume":"144","author":"Zhang","year":"2008","journal-title":"J. Biochem."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0245","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2017.03.015_b0250","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/0973-8398.55041","article-title":"Recent trends in protein and peptide drug delivery systems","volume":"3","author":"Gupta","year":"2009","journal-title":"Asian J. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0255","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/jps.22054","article-title":"Delivery of therapeutic proteins","volume":"99","author":"Pisal","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"13","key":"10.1016\/j.ejpb.2017.03.015_b0260","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1021\/bi101926u","article-title":"How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation","volume":"50","author":"Yang","year":"2011","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.ejpb.2017.03.015_b0265","first-page":"763","article-title":"Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches","volume":"4","author":"Yin","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejpb.2017.03.015_b0270","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2016.02.009","article-title":"A novel combined strategy for the physical PEGylation of polypeptides","volume":"226","author":"Ambrosio","year":"2016","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0275","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1021\/bc800258v","article-title":"Development of poly(ethylene glycol) conjugated lactoferrin for oral administration","volume":"19","author":"Nojima","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0280","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejpb.2007.07.009","article-title":"Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation","volume":"68","author":"Chae","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0285","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11095-008-9816-8","article-title":"Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels","volume":"26","author":"Tuesca","year":"2009","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0290","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2217\/nnm.15.36","article-title":"Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles","volume":"10","author":"Chaturvedi","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2017.03.015_b0295","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.2174\/092986712803251548","article-title":"Peptides as therapeutics with enhanced bioactivity","volume":"19","author":"Goodwin","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejpb.2017.03.015_b0300","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2174\/092986712799945003","article-title":"Converting peptides into drug leads by lipidation","volume":"19","author":"Zhang","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0305","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Li","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2017.03.015_b0310","doi-asserted-by":"publisher","first-page":"e1156805","DOI":"10.1080\/21688370.2016.1156805","article-title":"Chemically modified peptides and proteins - critical considerations for oral delivery","volume":"4","author":"Buckley","year":"2016","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0315","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12248-014-9670-z","article-title":"Lipid-based drug carriers for prodrugs to enhance drug delivery","volume":"17","author":"Zaro","year":"2015","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0320","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.addr.2012.07.012","article-title":"Fatty acids as therapeutic auxiliaries for oral and parenteral formulations","volume":"65","author":"Hackett","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0325","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1015992828666","article-title":"Synthesis of palmitoyl derivatives of insulin and their biological activities","volume":"6","author":"Hashimoto","year":"1989","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0330","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/1389557053765583","article-title":"Advancements in the anti-diabetes chemotherapeutics based on amino acids, peptides, and peptidomimetics","volume":"5","author":"Jain","year":"2005","journal-title":"Mini. Rev. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0335","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/17425247.2016.1142526","article-title":"Recent advances in oral delivery of peptide hormones","volume":"13","author":"Varamini","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0340","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s001250051529","article-title":"Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db\/db mice","volume":"43","author":"Joseph","year":"2000","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0345","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejpb.2007.07.009","article-title":"Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation","volume":"68","author":"Youn","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0350","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2008.09.091","article-title":"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db\/db mice","volume":"133","author":"Jin","year":"2009","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0355","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4155\/ppa.14.15","article-title":"Formulation strategies to improve oral peptide delivery","volume":"3","author":"Maher","year":"2014","journal-title":"Pharm. Pat. Anal."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b0360","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0365","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0370","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1023\/A:1016444808000","article-title":"Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells","volume":"13","author":"Schipper","year":"1996","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0375","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","article-title":"Oral insulin \u2013 a review of current status, diabetes","volume":"12","author":"Iyer","year":"2010","journal-title":"Obes. Met."},{"key":"10.1016\/j.ejpb.2017.03.015_b0380","first-page":"43","article-title":"Intestinal permeation enhancers for oral peptide delivery","author":"Maher","year":"2016","journal-title":"Adv. Drug Del. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0385","first-page":"1","article-title":"Peptides and proteins in pharmaceuticals","volume":"3","author":"Ratnaparkh","year":"2011","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.03.015_b0390","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.08.055","article-title":"The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers \u2013 an in vitro and in vivo comparison","author":"Weinheimer","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2017.03.015_b0395","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2017.03.015_b0400","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","article-title":"Oral delivery of macromolecular drugs: where we are after almost 100years of attempts","volume":"101","author":"Moroz","year":"2016","journal-title":"Adv. Drug Del. Rev."},{"issue":"33","key":"10.1016\/j.ejpb.2017.03.015_b0405","doi-asserted-by":"publisher","first-page":"8712","DOI":"10.1016\/j.biomaterials.2011.07.086","article-title":"Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins","volume":"32","author":"Sonaje","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.03.015_b0410","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biomaterials.2015.07.045","article-title":"Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: a controlled dual protein-drug delivery system","volume":"68","author":"Shrestha","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.03.015_b0415","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.msec.2016.08.083","article-title":"Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin","volume":"70","author":"Li","year":"2017","journal-title":"Mater. Sci. Eng., C"},{"key":"10.1016\/j.ejpb.2017.03.015_b0420","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2016.04.012","article-title":"Dual chitosan\/albumin-coated alginate\/dextran sulfate nanoparticles for enhanced oral delivery of insulin","volume":"232","author":"Lopes","year":"2016","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0425","first-page":"331","article-title":"Novel smart pH sensitive chitosan grafted alginate hydrogel microcapsules for oral protein delivery: II. Evaluation of the swelling behavior","volume":"7","author":"Eldin","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b0430","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2010.08.020","article-title":"Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution","volume":"400","author":"Vllasaliu","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.015_b0435","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.carbpol.2014.06.045","article-title":"pH sensitive N-succinyl chitosan grafted polyacrylamide hydrogel for oral insulin delivery","volume":"112","author":"Mukhopadhyay","year":"2014","journal-title":"Carbohyd. Polym."},{"key":"10.1016\/j.ejpb.2017.03.015_b0440","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijbiomac.2014.08.040","article-title":"PH-sensitive chitosan\/alginate core\u2013shell nanoparticles for efficient and safe oral insulin delivery","volume":"72","author":"Mukhopadhyay","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2017.03.015_b0445","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2015.12.008","article-title":"Efficient mucus permeation and tight junction opening by dissociable \u201cmucus-inert\u201d agent coated trimethyl chitosan nanoparticles for oral insulin delivery","volume":"222","author":"Liu","year":"2015","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0450","first-page":"3165","article-title":"In vivo evaluation of thiolated chitosan tablets for oral insulin delivery","volume":"103","author":"Millotti","year":"2014","journal-title":"Pharm., Drug Del. Pharm. Technol."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0455","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.addr.2005.07.002","article-title":"Thiomers: a new generation of mucoadhesive polymers","volume":"57","author":"Bernkop-Schnurch","year":"2005","journal-title":"Adv. Drug Del. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0460","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1166\/jbn.2015.1924","article-title":"Chitosan-modified cationic amino acid nanoparticles as a novel oral delivery system for insulin","volume":"11","author":"Abbad","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0465","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0470","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0475","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1002\/jps.23640","article-title":"Preparation and characterization of insulin\u2013surfactant complexes for loading into lipid-based drug delivery systems","volume":"102","author":"Li","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0480","series-title":"Oral Delivery of Macromolecular Drugs: Barriers, Strategies and Future Trends- Low Molecular Mass Permeation Enhancers In Oral Delivery Of Macromolecular Drugs","author":"Schn\u00fcrc","year":"2009"},{"key":"10.1016\/j.ejpb.2017.03.015_b0485","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molstruc.2010.11.049","article-title":"Adsorption investigation of Ma-Dtpa chelating resin for Ni(Ii) and Cu(II) using experimental and DFT methods","volume":"986","author":"Zhao","year":"2011","journal-title":"J. Mol. Struct."},{"issue":"9","key":"10.1016\/j.ejpb.2017.03.015_b0490","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.biomaterials.2011.12.038","article-title":"Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery","volume":"33","author":"Sua","year":"2012","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0495","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3923\/jms.2015.209.220","article-title":"Oral delivery of insulin for treatment of diabetes: classical challenges and current opportunities","volume":"15","author":"Ansari","year":"2015","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0500","unstructured":"L. Hovgaard, H. Refsgaard, T.B. Kjeldsen, et al., Pharmaceutical Composition For Oral Insulin Administration Comprising A Tablet Core And An Anionic Copolymer Coating, Wo 2015010927 A1.2015"},{"key":"10.1016\/j.ejpb.2017.03.015_b0505","first-page":"1","article-title":"Peptide and protein delivery at a glance","volume":"2","author":"Aboofazeli","year":"2003","journal-title":"Iran J. Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0510","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1517\/17425247.2014.917077","article-title":"Oral peptide and protein delivery: intestinal obstacles and commercial prospects","volume":"11","author":"Smart","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0515","first-page":"1057","article-title":"Novel approaches for oral delivery of insulin and current status of oral insulin products","volume":"3","author":"Kinesh","year":"2010","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0520","first-page":"61","article-title":"A review on novel approaches for oral delivery of insulin","volume":"5","author":"Neha","year":"2015","journal-title":"J. Drug Del. Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0525","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijpharm.2005.04.016","article-title":"A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats","volume":"298","author":"Cilek","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0530","first-page":"1","article-title":"Role of protease inhibitors in Insulin therapy of diabetes: are these beneficial?","volume":"4","author":"Ansari","year":"2015","journal-title":"Bull. Environ. Pharmacol. Life Sci."},{"issue":"15\u201316","key":"10.1016\/j.ejpb.2017.03.015_b0535","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.drudis.2012.03.002","article-title":"Cell-penetrating peptides: classes, origin, and current landscape","volume":"17","author":"Milletti","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2017.03.015_b0540","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pharmthera.2015.07.003","article-title":"Cell-penetrating peptides transport therapeutics into cells","volume":"154","author":"Ramsey","year":"2015","journal-title":"Pharmacol. Therap."},{"key":"10.1016\/j.ejpb.2017.03.015_b0545","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2016.03.020","article-title":"Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems","volume":"229","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0550","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0555","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejpb.2015.04.030","article-title":"Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium","volume":"94","author":"Kamei","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"20","key":"10.1016\/j.ejpb.2017.03.015_b0560","doi-asserted-by":"publisher","first-page":"10706","DOI":"10.1039\/C6NR00294C","article-title":"In vivodual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy","volume":"8","author":"Ara\u00fajo","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2017.03.015_b0565","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2016.05.015","article-title":"Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates","volume":"233","author":"Sheng","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0570","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpharm.2009.07.022","article-title":"Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins","volume":"381","author":"Khafagy","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0575","first-page":"362","article-title":"Mucoadhesive drug delivery systems, a review","volume":"5","author":"Shahid","year":"2016","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0580","first-page":"25","article-title":"Novel approaches for insulin delivery: current status","volume":"7","author":"Varshney","year":"2012","journal-title":"Int. J. Ther. App."},{"key":"10.1016\/j.ejpb.2017.03.015_b0585","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jddst.2015.06.016","article-title":"A focus on mucoadhesive polymers and their application in buccal dosage forms","volume":"32","author":"Russo","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b0590","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ijpharm.2014.07.049","article-title":"Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery","volume":"473","author":"Andreani","year":"2014","journal-title":"Int. J. pharma."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0595","first-page":"1","article-title":"Novel carrier systems for oral delivery of insulin","volume":"1","author":"Shinde","year":"2013","journal-title":"Asian J. Pharm. Tech. Inno."},{"key":"10.1016\/j.ejpb.2017.03.015_b0600","series-title":"Proteins and Peptides: Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes","author":"Mrsny","year":"2010"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0605","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11095-014-1513-1","article-title":"The glucose-lowering potential of exenatide delivered orally via goblet cell- targeting nanoparticles","volume":"32","author":"Li","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.03.015_b0610","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.carbpol.2015.09.103","article-title":"Positive\/negative surface charge of chitosan based nanogels and its potential influence on oral insulin delivery","volume":"136","author":"Wang","year":"2016","journal-title":"Carbohyd. Polym."},{"key":"10.1016\/j.ejpb.2017.03.015_b0615","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2016.04.024","article-title":"Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model","volume":"232","author":"Shrestha","year":"2016","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0620","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s10439-016-1558-x","article-title":"Delivery of exenatide and insulin using mucoadhesive intestinal devices","volume":"44","author":"Gupta","year":"2016","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2017.03.015_b0625","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1773-2247(10)50007-8","article-title":"Thiolated chitosan","volume":"20","author":"Sakloetsakun","year":"2010","journal-title":"J. Drug Del. Sci. Tech."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b0630","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijpharm.2014.05.047","article-title":"In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin","volume":"472","author":"Hintzen","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.015_b0635","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijbiomac.2013.08.002","article-title":"Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration","volume":"61","author":"Sakloetsakun","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0640","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/md13052890","article-title":"Alginate hydrogels coated with chitosan for wound dressing","volume":"13","author":"Straccia","year":"2015","journal-title":"Mar. Drug."},{"key":"10.1016\/j.ejpb.2017.03.015_b0645","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijbiomac.2016.07.019","article-title":"Development of amphoteric alginate\/aminated chitosan coated microbeads for oral protein delivery","volume":"92","author":"Omer","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0650","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejpb.2010.09.016","article-title":"Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin","volume":"77","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0655","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3109\/03639045.2014.947507","article-title":"Development of \u03b2-cyclodextrin-based sustained release microparticles for oral insulin delivery","volume":"41","author":"D\u2019Souza","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.015_b0660","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jddst.2015.06.020","article-title":"Reduction of theinvivoburst release of insulin-loaded microparticles","volume":"30","author":"Hasan","year":"2015","journal-title":"J. Drug Del. Sci. Technol."},{"key":"10.1016\/j.ejpb.2017.03.015_b0665","doi-asserted-by":"publisher","first-page":"e86064","DOI":"10.1371\/journal.pone.0086064","article-title":"Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2017.03.015_b0670","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6673-2-16","article-title":"Nanotechnology-based drug delivery systems","volume":"2","author":"Suri","year":"2007","journal-title":"J. Occup. Med. Toxicol."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0675","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B"},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0680","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4155\/tde.12.40","article-title":"Polymer-based oral peptide nanomedicines","volume":"3","author":"Herrero","year":"2012","journal-title":"Ther. Deliv."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0685","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2174\/0929866521666140807114240","article-title":"Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles","volume":"21","author":"Patel","year":"2014","journal-title":"Protein Pept. Lett."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0690","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/nnm.09.110","article-title":"Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery","volume":"5","author":"Roger","year":"2015","journal-title":"Nanomedicine (Lond.)"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0695","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0939-6411(00)00084-9","article-title":"Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?","volume":"50","author":"Jung","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0700","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v22.i5.10","article-title":"Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies","volume":"22","author":"Galindo-Rodriguez","year":"2005","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0705","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/17425247.5.1.45","article-title":"Strategies for the oral delivery of insulin","volume":"5","author":"Damg\u00e9","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2017.03.015_b0710","series-title":"Drug Delivery: Principles and Applications","article-title":"Oral protein and peptide drug delivery","author":"Rick","year":"2005"},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0715","doi-asserted-by":"publisher","first-page":"46","DOI":"10.18433\/J3RC77","article-title":"Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy","volume":"12","author":"Bansal","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0720","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1039\/c2sm06811g","article-title":"Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling","volume":"8","author":"Xu","year":"2012","journal-title":"Soft Matter"},{"key":"10.1016\/j.ejpb.2017.03.015_b0725","series-title":"Peptide and Protein Delivery","author":"Van der Valle","year":"2011"},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0730","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.biomaterials.2010.12.044","article-title":"The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo","volume":"32","author":"Nguyen","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.03.015_b0735","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.phrs.2016.05.016","article-title":"Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats","volume":"110","author":"Salvionia","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2017.03.015_b0740","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msec.2016.06.059","article-title":"A composite hydrogel system containing glucose-responsive nanocarriers for oral delivery of insulin","volume":"69","author":"Li","year":"2016","journal-title":"Mater. Sci. Eng., C"},{"issue":"9","key":"10.1016\/j.ejpb.2017.03.015_b0745","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1248\/bpb.29.1790","article-title":"Nanocarriers: promising vehicle for bioactive drugs","volume":"29","author":"Rawat","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2017.03.015_b0750","series-title":"Nanoparticles for Pharmaceutical Applications","article-title":"Lipid nanoparticles (SLN and NLC) for drug delivery","author":"Souto","year":"2007"},{"key":"10.1016\/j.ejpb.2017.03.015_b0755","series-title":"Handbook of Pharmaceutical Controlled Release Technology","article-title":"Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs","author":"Muller","year":"2000"},{"key":"10.1016\/j.ejpb.2017.03.015_b0760","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.msec.2016.05.119","article-title":"Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies","volume":"68","author":"Moritz","year":"2016","journal-title":"Mater. Sci. Eng."},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0765","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s11095-010-0130-x","article-title":"Phospholipids and lipid-based formulations in oral drug delivery","volume":"27","author":"Fricker","year":"2010","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.ejpb.2017.03.015_b0770","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ijpharm.2016.07.016","article-title":"Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery","volume":"511","author":"Boushra","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0775","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.xphs.2016.02.018","article-title":"Methocel-lipid hybrid nanocarrier for efficient oral insulin delivery","volume":"105","author":"Boushra","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"33","key":"10.1016\/j.ejpb.2017.03.015_b0780","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.1016\/j.biomaterials.2014.07.026","article-title":"The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium","volume":"35","author":"Ara\u00fajo","year":"2014","journal-title":"Biomaterials"},{"issue":"26","key":"10.1016\/j.ejpb.2017.03.015_b0785","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.1016\/j.biomaterials.2014.05.020","article-title":"Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering","volume":"35","author":"Shahbazi","year":"2014","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0790","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jfda.2015.01.007","article-title":"Application of polymeric nanoparticles and micelles in insulin oral delivery","volume":"23","author":"Alai","year":"2015","journal-title":"J. Food Drug Anal."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0795","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1166\/jbn.2013.1572","article-title":"N-octyl-N-Arginine chitosan micelles as an oral delivery system of insulin","volume":"9","author":"Zhang","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2017.03.015_b0800","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0805","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2007.10.023","article-title":"Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes","volume":"125","author":"Thirawong","year":"2008","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.ejpb.2017.03.015_b0810","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1016\/j.lfs.2004.05.027","article-title":"The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer","volume":"75","author":"Degim","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0815","first-page":"1155","article-title":"Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation","volume":"6","author":"Niu","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2017.03.015_b0820","unstructured":"M. Niu, Y. Lu, L. Hovgaard, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose 81(2) (2012) 265\u2013272."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0825","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nano.2013.07.011","article-title":"Biotinylated liposomes as potential carriers for the oral delivery of insulin","volume":"10","author":"Zhang","year":"2014","journal-title":"Nanomed. Nanotech. Biol. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0830","first-page":"39","article-title":"Review on microemulsion as futuristic drug delivery","volume":"5","author":"Muzaffar","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0835","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/187221108786241679","article-title":"Microemulsions: a novel approach to enhanced drug delivery","volume":"2","author":"Talegaonkar","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0840","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejpb.2010.07.002","article-title":"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats","volume":"76","author":"Sharma","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.015_b0845","unstructured":"R.S. Mody, A.K. Gupta, S. Paul, Microemulsion formulation for biologicals, WO 2011004395 A1.2011."},{"key":"10.1016\/j.ejpb.2017.03.015_b0850","unstructured":"Oral Pharmaceutical Formulation of BCS Class III Molecules, US 20150165032 A1.2015."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0855","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/10717544.2013.819611","article-title":"Oral delivery of therapeutic proteins and peptides: a review on recent developments","volume":"20","author":"Gupta","year":"2013","journal-title":"Drug Del."},{"issue":"9","key":"10.1016\/j.ejpb.2017.03.015_b0860","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","article-title":"Polymeric nanoparticle drug delivery technologies for oral delivery applications","volume":"12","author":"Pridgen","year":"2015","journal-title":"Exp Opin. On Drug Del."},{"issue":"4","key":"10.1016\/j.ejpb.2017.03.015_b0865","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/md13041819","article-title":"Winnicka. stability of chitosan\u2014a challenge for pharmaceutical and biomedical applications","volume":"13","author":"Szyma\u0144ska","year":"2015","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejpb.2017.03.015_b0870","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trac.2015.06.014","article-title":"PLGA-based nanoparticles: a new paradigm in biomedical applications","volume":"80","author":"Sharma","year":"2016","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.ejpb.2017.03.015_b0875","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0168-3659(03)00328-6","article-title":"Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano and microparticles","volume":"92","author":"Jayanth","year":"2003","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0880","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0885","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3109\/03639045.2014.972412","article-title":"In vitro lipolysis tests on lipid nanoparticles: comparison between lipase\/co-lipase and pancreatic extract","volume":"4","author":"Jannin","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0890","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications","volume":"8","author":"M\u00fcller","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0895","first-page":"80","article-title":"Solid lipid nanoparticles: a review","volume":"2","author":"Ekambaram","year":"2012","journal-title":"Sci. Rev. Chem. Commun."},{"key":"10.1016\/j.ejpb.2017.03.015_b0900","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejpb.2016.06.016","article-title":"Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin","volume":"107","author":"Latorre","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejpb.2017.03.015_b0905","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/BF02867128","article-title":"Oral insulin-fact or fiction? Possibilities of achieving oral delivery for insulin","volume":"8","author":"Gowthamarajan","year":"2003","journal-title":"Resonance"},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0910","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jfda.2015.01.007","article-title":"Application of polymeric nanoparticles and micelles in insulin oral delivery","volume":"23","author":"Alai","year":"2015","journal-title":"J. Food Drug Anal."},{"issue":"7","key":"10.1016\/j.ejpb.2017.03.015_b0915","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3109\/1061186X.2014.934688","article-title":"Polymeric micelles as drug carriers: their lights and shadows","volume":"22","author":"Yokoyama","year":"2014","journal-title":"J. Drug Target."},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0920","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.3390\/molecules18066734","article-title":"Eudragit\u00ae L100\/N-trimethylchitosan chloride microspheres for oral insulin delivery","volume":"18","author":"Marais","year":"2013","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.ejpb.2017.03.015_b0925","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0930","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1208\/s12248-012-9441-7","article-title":"In vitroandin vivoevaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery","volume":"15","author":"Liu","year":"2014","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b0935","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jconrel.2008.03.018","article-title":"Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme","volume":"129","author":"Cheng","year":"2008","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.ejpb.2017.03.015_b0940","first-page":"1888","article-title":"A review on microemulsion based system","volume":"2","author":"Madhav","year":"2011","journal-title":"IJPSR"},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0945","first-page":"37","article-title":"Microemulsions as carrier for novel drug delivery: a review","volume":"10","author":"Senthil","year":"2011","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0950","first-page":"1800","article-title":"Microemulsion \u2013 prophesy of drug delivery system","volume":"3","author":"Sruthi","year":"2014","journal-title":"World J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0955","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejpb.2015.03.027","article-title":"Effect of mucoadhesive polymers on thein vitroperformance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models","volume":"93","author":"Andreania","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"19\u201320","key":"10.1016\/j.ejpb.2017.03.015_b0960","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ejpb.2017.03.015_b0965","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3109\/10717544.2015.1043472","article-title":"Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec)","volume":"23","author":"Zhu","year":"2016","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b0970","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40005-016-0253-0","article-title":"Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future","volume":"46","author":"Bashyal","year":"2016","journal-title":"J. Pharm. Invest."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b0975","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/ijms17020263","article-title":"Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease","volume":"17","author":"Dinca","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0980","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2012.09.032","article-title":"Penetration enhancers","volume":"64","author":"Williams","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ejpb.2017.03.015_b0985","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.4155\/tde.11.114","article-title":"Oral peptide delivery prioritizing the leading technologies","volume":"2","author":"Brayden","year":"2011","journal-title":"Ther. Deliv."},{"issue":"10","key":"10.1016\/j.ejpb.2017.03.015_b0990","first-page":"404","article-title":"Oral insulin \u2013 a challenging approach in insulin delivery","volume":"4","author":"Krishnan","year":"2015","journal-title":"World. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b0995","series-title":"Handbook of Encapsulation and Controlled Release. Polymeric Nano\/Microparticles for Oral Delivery of Proteins and Peptides","first-page":"1361","author":"Mishra","year":"2016"},{"issue":"7","key":"10.1016\/j.ejpb.2017.03.015_b1000","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.03.015_b1005","doi-asserted-by":"publisher","first-page":"18039","DOI":"10.1038\/srep18039","article-title":"Variant fatty acid-like molecules conjugation, novel approaches for extending the stability of therapeutic peptides","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejpb.2017.03.015_b1010","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of pegylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.ejpb.2017.03.015_b1015","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijpharm.2016.07.003","article-title":"New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach","volume":"511","author":"Pallagi","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2017.03.015_b1020","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijpharm.2015.06.018","article-title":"Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation","volume":"491","author":"Pallagi","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2017.03.015_b1025","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/ics.12248","article-title":"Optimization and development of stable w\/o\/w cosmetic multiple emulsions by means of the quality by design approach","volume":"38","author":"Kovacs","year":"2016","journal-title":"Int. J. Cosm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b1030","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejps.2016.12.020","article-title":"Development of nanostructured lipid carriers containing salicylic acid for dermal use based on the quality by design method","volume":"99","author":"Kov\u00e1cs","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.03.015_b1035","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/DDDT.S116443","article-title":"Development of a microparticle-based DPI formulation of ciprofloxacin hydrochloride applying the QbD approach","volume":"10","author":"Karimi","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2017.03.015_b1040","series-title":"11th Central European Symposium on Pharmaceutical Technology, Belgrad, Conference Abstract Book","first-page":"33","article-title":"Regulatory science based drug formulation -model proposal for QBD in R&D phase","author":"Csoka","year":"2016"},{"key":"10.1016\/j.ejpb.2017.03.015_b1045","unstructured":"Quality by Design for Biotechnology Products\u2014Part 1, A PhRMA Working Group's advice on applying QbD to biotech. BioPharm International, vol. 22, Issue 11, 2009"},{"key":"10.1016\/j.ejpb.2017.03.015_b1050","unstructured":"ICH guideline Q8 (R2) on pharmaceutical development, EMA, 2014, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002872.pdf>."},{"key":"10.1016\/j.ejpb.2017.03.015_b1055","unstructured":"ICH guideline Q9 on quality risk management, EMA, 2014, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002873.pdf>."},{"key":"10.1016\/j.ejpb.2017.03.015_b1060","unstructured":"ICH guideline Q10 on pharmaceutical quality system, EMA, 2014, <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002871.pdf>."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T14:54:26Z","timestamp":1658847266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116309389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":212,"alternative-id":["S0939641116309389"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.015","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel strategies in the oral delivery of antidiabetic peptide drugs \u2013 Insulin, GLP 1 and its analogs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}